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Clinical PerspectiveWhat Is New?This is the first study to demonstrate the safety of cardiopulmonary exercise testing in patients with arrhythmogenic right ventricular (RV) cardiomyopathy/dysplasia, a population of patients in whom many clinicians may be hesitant to recommend exercise testing.In addition, it shows how traditional parameters from cardiopulmonary exercise testing, such as peak oxygen consumption, may be less beneficial in this unique population. Instead, ventilatory efficiency may have utility in risk stratifying patients with arrhythmogenic RV cardiomyopathy/dysplasia.What Are the Clinical Implications?Arrhythmogenic RV cardiomyopathy/dysplasia is a rare disorder, but with increasing recognition, cascade screening, and implantable cardioverter‐defibrillator implantation, patients with arrhythmogenic RV cardiomyopathy/dysplasia are surviving longer and progressing toward heart failure.Given the unique nature of this predominantly RV cardiomyopathy, the presentation and management of these patients differs from patients with traditional heart failure.Therefore, risk stratification and timely therapeutic interventions can be challenging. Cardiopulmonary exercise testing provides an objective tool in the clinician\'s arsenal to potentially identify higher‐risk patients appropriate for heart transplant referral.

Introduction {#jah34777-sec-0008}
============

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic cardiomyopathy marked by fibrofatty replacement of cardiomyocytes, resulting in right ventricular (RV) dysfunction and life‐threatening ventricular arrhythmias.[1](#jah34777-bib-0001){ref-type="ref"}, [2](#jah34777-bib-0002){ref-type="ref"}, [3](#jah34777-bib-0003){ref-type="ref"} Sudden cardiac death was a frequent initial presentation of disease but with increasingly prompt recognition and intervention (such as implantation of cardiac defibrillators), patients are living longer to develop other progressive manifestations, primarily right‐ and left‐sided heart failure (HF).[2](#jah34777-bib-0002){ref-type="ref"}, [4](#jah34777-bib-0004){ref-type="ref"}, [5](#jah34777-bib-0005){ref-type="ref"}, [6](#jah34777-bib-0006){ref-type="ref"}

Exercise intolerance is a cardinal manifestation of HF. Cardiopulmonary exercise testing (CPET) allows assessment of maximal exercise capacity by measuring peak oxygen consumption (pVO~2~), as well as ventilatory patterns during submaximal exercise.[7](#jah34777-bib-0007){ref-type="ref"} CPET can be used to inform prognosis and patient selection for advanced HF therapies, such as cardiac transplantation and ventricular assist devices.[8](#jah34777-bib-0008){ref-type="ref"}, [9](#jah34777-bib-0009){ref-type="ref"} pVO~2~ is the best‐studied variable in HF, but more recently ventilatory efficiency (Ve/VCO~2~ slope) has been shown to have prognostic implications, particularly in RV cardiomyopathies.[10](#jah34777-bib-0010){ref-type="ref"}, [11](#jah34777-bib-0011){ref-type="ref"}, [12](#jah34777-bib-0012){ref-type="ref"}, [13](#jah34777-bib-0013){ref-type="ref"}

The role of CPET has not been described in patients with ARVC/D. This may be because of the rarity of the disease, hesitancy to refer because of perceived arrhythmic risk during exercise, and limited understanding of application of CPET in RV predominant disease states. The aim of this study was to demonstrate the safety and prognostic ability of CPET in a large US ARVC/D cohort. Specifically, we hypothesized that CPET is safe to perform and that Ve/VCO~2~ slope may serve as a prognostic marker in patients with ARVC/D.

Methods {#jah34777-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request.

Study Population {#jah34777-sec-0010}
----------------

The Johns Hopkins ARVC/D Program Registry was established in 1999 and prospectively enrolls patients referred for possible ARVC/D and their family members. We queried the registry and included patients who (1) met the 2010 Revised Task Force Criteria for ARVC/D by last follow‐up, (2) had undergone CPET at any point in their disease course, and (3) were aged ≥18 years at the time of CPET. The Johns Hopkins Institutional Review Board approved the study protocol. Written, informed consent was obtained from each patient.

Clinical Data Collection {#jah34777-sec-0011}
------------------------

Baseline demographic and clinical data, including ARVC/D presentation, comorbidities, symptoms, medications, implantable cardioverter‐defibrillator (ICD), imaging studies, and clinical events, were obtained from the ARVC/D registry accessed on August 15, 2018. The data set includes medical records and patient questionnaires about major clinical events, which are updated prospectively at yearly intervals after patient enrollment. For the subset of patients who underwent a CPET, additional chart review and medical record collection were performed up to data query date of August 15, 2018. Almost all the patients had multiple transthoracic echocardiograms during the study period. Data from the transthoracic echocardiogram closest in absolute time, either before or after, to CPET were used to assess ventricular function, as follows: (1) RV dilation and dysfunction were qualitatively assessed and categorized as normal/mild or moderate/severe on the basis of transthoracic echocardiogram; and (2) left ventricular (LV) dysfunction was defined as LV systolic ejection fraction \<45%, and LV diastolic dimension was measured in the parasternal long axis on transthoracic echocardiogram. The presence of HF at the time of CPET was determined using patient symptoms and physical examination findings for HF during clinical encounters, as we have previously described.[4](#jah34777-bib-0004){ref-type="ref"} HF signs and symptoms included shortness of breath, dyspnea on exertion, fatigue, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, abdominal swelling/ascites, S3 summation gallop, jugular venous distention, and rales. Life‐threatening ventricular arrhythmias were defined as a composite of spontaneous sustained ventricular tachycardia (VT), appropriate ICD intervention, sudden cardiac arrest, or sudden cardiac death. The primary outcome was transplant‐free survival.

CPET Data {#jah34777-sec-0012}
---------

Cardiopulmonary exercise test result reports were abstracted and included if VO~2~ testing and respiratory exchange ratio (RER) data were available. Patient height and weight, pulmonary function parameters, absolute and normalized pVO~2~, percentage of predicted pVO~2~, VO~2~ at anaerobic threshold, Ve/VCO~2~ slope, RER, exercise protocol used, peak heart rate, and reason for stopping were recorded for each CPET. Adverse events were adjudicated from CPET visit documentation, which routinely includes patient symptoms and procedural complications, CPET ECG, and chart review of subsequent clinical encounters. If a patient underwent multiple CPETs, all CPETs were used for safety analysis; however, only the patient\'s last CPET was used for the remainder of analyses. A test was considered submaximal if RER \<1.05 and thus excluded from peak VO~2~ analyses. On the basis of established prognostic CPET variable cutoffs, subjects were divided into groups by pVO~2~ (≤14 or \>14 mL/kg per minute)[10](#jah34777-bib-0010){ref-type="ref"} and Ve/VCO~2~ slope (≤34 or \>34).[8](#jah34777-bib-0008){ref-type="ref"}, [13](#jah34777-bib-0013){ref-type="ref"} Sensitivity analyses were also performed using Ve/VCO~2~ slope cutoff of 36 and percentage of predicted pVO~2~ (\<70% versus ≥70%), given the utility of this latter variable over pVO~2~ in a younger cohort.

Statistical Analysis {#jah34777-sec-0013}
--------------------

All continuous variables are presented as median and interquartile range (IQR) and categorical variables as numbers (percentages). We performed bivariate analyses to compare baseline variables according to pVO~2~ and Ve/VCO~2~ slope categories. In addition, subjects were compared on the basis of whether they met the end point of death or transplant. Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test. Overall and transplant‐free survival rates were estimated using the Kaplan‐Meier method. Differences in survival between groups were evaluated using the log‐rank test. Two‐sided *P* values were used for all tests, and *P*\<0.050 was considered statistically significant. Statistical analyses were performed using Stata, version 14.2.

Results {#jah34777-sec-0014}
=======

Study Population {#jah34777-sec-0015}
----------------

A total of 50 CPETs were performed in 38 patients meeting the ARVC/D 2010 Revised Task Force Criteria. Eight patients had multiple CPETs over the study period, with the interval between testing ranging from 7 months to 8 years; 2 patients had 3 CPETs, and 1 patient underwent 4 CPETs. Baseline characteristics are described in Table [1](#jah34777-tbl-0001){ref-type="table"}. Most patients had an identified pathogenic mutation associated with ARVC/D (n=27 \[71%\]). In regard to arrhythmic risk, most patients had a history of life‐threatening ventricular arrhythmia before CPET (n=32 \[84%\]) and were on a β blocker at the time of CPET (n=32 \[84%\]). Clinical HF was present in 23 patients (61%). LV systolic dysfunction was present in 9 patients (24%). Medical comorbidities were uncommon.

###### 

Baseline Characteristics of Patients With ARVC/D Undergoing CPET

  Variable                                      No Transplant (n=28)   Transplant (n=10)   *P* Value[a](#jah34777-note-0002){ref-type="fn"}   All Patients (n=38)
  --------------------------------------------- ---------------------- ------------------- -------------------------------------------------- ---------------------
  Men                                           13 (46)                8 (80)              0.136                                              21 (55)
  White                                         27 (96)                10 (100)            1.000                                              37 (97)
  Age at CPET, y                                38.4 (24.3)            42.0 (13.3)         0.765                                              38.8 (17.4)
  Proband                                       25 (89)                9 (90)              1.000                                              34 (89)
  Pathogenic mutation, any                      22 (79)                5 (50)              0.116                                              27 (71)
  Type of mutation                                                                         0.564                                              
  *PKP2*                                        10 (36)                5 (50)                                                                 15 (39)
  *DSP*                                         5 (18)                 0 (0)                                                                  5 (13)
  *DSG2*                                        1 (4)                  0 (0)                                                                  1 (3)
  *DSC2*                                        1 (4)                  0 (0)                                                                  1 (3)
  *JUP*                                         1 (4)                  0 (0)                                                                  1 (3)
  *TMEM43*                                      1 (4)                  0 (0)                                                                  1 (3)
  *PLN*                                         1 (4)                  0 (0)                                                                  1 (3)
  *CH/HO/DG*                                    2 (7)                  0 (0)                                                                  2 (5)
  Age at presentation, y                        23.0 (22.8)            29.9 (16.8)         0.507                                              26.0 (22.0)
  Age at meeting task force criteria, y         31.1 (23.3)            33.1 (18.7)         0.974                                              31.1 (22.0)
  No. of major criteria met                     3.0 (2.0)              3.0 (1.0)           0.657                                              3.0 (2.0)
  No. of minor criteria met                     3.0 (2.5)              3.0 (3.0)           0.695                                              3.0 (3.0)
  Total No. of criteria met                     6.0 (2.5)              7.0 (4.0)           0.471                                              6.0 (3.0)
  Type of presentation                                                                     0.362                                              
  Sudden cardiac arrest                         2 (7)                  1 (10)                                                                 3 (8)
  Symptomatic                                   20 (71)                9 (90)                                                                 29 (76)
  Asymptomatic                                  6 (21)                 0 (0)                                                                  6 (16)
  Hypertension                                  1 (4)                  1 (10)              0.462                                              2 (5)
  Coronary artery disease                       0 (0)                  0 (0)               1.000                                              0 (0)
  Cerebrovascular accident                      1 (4)                  0 (0)               1.000                                              1 (3)
  Diabetes mellitus                             0 (0)                  0 (0)               1.000                                              0 (0)
  Hyperlipidemia                                2 (7)                  2 (20)              0.279                                              4 (11)
  β Blocker                                     25 (89)                7 (70)              0.310                                              32 (84)
  ACEi/ARB                                      14 (54)                6 (60)              1.000                                              21 (55)
  Aldosterone receptor blocker                  6 (21)                 3 (30)              0.673                                              9 (24)
  Antiarrhythmic                                13 (46)                7 (70)              0.278                                              20 (53)
  ICD                                           23 (82)                9 (90)              1.000                                              32 (84)
  Clinical heart failure                        13 (46)                10 (100)            0.003                                              23 (61)
  LVEF, %                                       55 (13)                55 (15)             0.310                                              55 (15)
  LVEF \<45%                                    6 (21)                 3 (30)              0.673                                              9 (24)
  Left ventricular end diastolic diameter, cm   5.0 (0.7)              4.9 (0.4)           0.416                                              4.9 (0.7)
  Moderate/severe RV dysfunction                13 (46)                6 (60)              0.714                                              19 (50)
  Moderate/severe RV dilation                   11 (39)                8 (80)              0.062                                              19 (50)

Categorical variables are expressed as number (percentage). Continuous variables are expressed as median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARVC/D, arrhythmogenic right ventricular cardiomyopathy/dysplasia; CPET, cardiopulmonary exercise testing; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; RV, right ventricle.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

CPET Safety {#jah34777-sec-0016}
-----------

CPET protocols used were as follows: 28 staged cycle, 6 Bruce treadmill, 4 Naughton treadmill, 3 unspecified treadmill, and 9 unknown. Most CPETs were performed with patients having an ICD (n=43/50 \[86%\]). There were no deaths, sustained arrhythmias, ICD interventions, or other life‐threatening events during or immediately after any CPET. CPET was terminated in 3 (6%) because of heart rate approaching ICD threshold for ventricular arrhythmia therapies. Arrhythmias were nonsustained, infrequent, and asymptomatic, as follows: premature ventricular contractions (n=7 \[14%\]), bigeminy (n=2 \[4%\]), and nonsustained VT (n=2 \[4%\]).

CPET Parameters and Clinical Characteristics {#jah34777-sec-0017}
--------------------------------------------

CPET performance characteristics are shown in Table [2](#jah34777-tbl-0002){ref-type="table"}. Median normalized pVO~2~ was 21.1 (IQR, 9.8) mL/kg per minute and median Ve/VCO~2~ slope was 30.0 (IQR, 8.3). Twenty‐nine patients achieved an RER ≥1.05, and 35 patients had Ve/VCO~2~ slope reported. The 9 submaximal tests (RER \<1.05) were limited because of fatigue (n=2), heart rate approaching ICD therapy threshold (n=2), dyspnea/leg tingling, dizziness, patient fear of arrhythmia, per patient request, and unknown.

###### 

CPET Characteristics in Patients With ARVC/D

  Characteristic                                       No Transplant (n=28)   Transplant (n=10)   *P* Value[a](#jah34777-note-0005){ref-type="fn"}   Total (n=38)
  ---------------------------------------------------- ---------------------- ------------------- -------------------------------------------------- --------------
  Absolute pVO~2~, mL/min                              1697 (766)             1232 (1056)         0.037                                              1659 (785)
  Normalized pVO~2~, mL/kg per min                     22.6 (10.9)            15.8 (10.3)         0.006                                              21.1 (9.8)
  Predicted VO~2~, %                                   73.0 (34.6)            55.0 (31.3)         0.084                                              71.5 (36.1)
  Ve/VCO~2~ slope (n=35)                               29.0 (5.6)             37.2 (12.3)         \<0.001                                            30.0 (8.3)
  VO~2~ at anaerobic threshold (n=32), mL/kg per min   14.7 (6.2)             11.5 (5.6)          0.068                                              13.0 (5.3)
  RER                                                  1.14 (0.14)            1.08 (0.11)         0.353                                              1.10 (0.13)
  Peak HR, beats per min                               155 (51)               121 (31)            0.111                                              140 (51)
  Predicted HR, %                                      82 (22)                68 (17)             0.101                                              81 (24)
  Submaximal test (RER \<1.05)                         6 (21)                 3 (30)              0.673                                              9 (24)

All variables are expressed as median (interquartile range) and n=38, unless noted. ARVC/D indicates arrhythmogenic right ventricular cardiomyopathy/dysplasia; CPET, cardiopulmonary exercise testing; HR, heart rate; pVO~2~, peak VO~2~; RER, respiratory exchange ratio; Ve/VCO~2~ slope, ventilatory efficiency; VO~2~, oxygen consumption.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

When compared with patients with pVO~2~ \>14 mL/kg per minute, those with pVO~2~ ≤14 mL/kg per minute were more often men (10/25 \[40%\] versus 4/4 \[100%\]; *P*=0.042) but there were no observed differences in age, mutation presence, comorbidities, or presence of clinical HF (Table [3](#jah34777-tbl-0003){ref-type="table"}). Patients with pVO~2~ ≤14 mL/kg per minute had higher Ve/VCO~2~ slope compared with patients with pVO~2~ \>14 mL/kg per minute (51.0 \[IQR, 26.4\] versus 29.6 \[IQR, 6.1\]; *P*=0.009). In the sensitivity analysis using percentage of predicted pVO~2~ (\<70% versus ≥70%), baseline differences were notable for higher proportion of men (8/11 \[73%\] versus 6/18 \[33%\]; *P*=0.042) and larger LV diastolic dimension (5.1 \[IQR, 1.0\] versus 4.8 \[IQR, 0.8\] cm; *P*=0.016) in the group with pVO~2~ \<70% (Table [4](#jah34777-tbl-0004){ref-type="table"}).

###### 

Comparison of Patient Characteristics Based on Normalized pVO~2~ Category

  Characteristic                                pVO~2~ ≤14 mL/kg per min (n=4)   pVO~2~ \>14 mL/kg per min (n=25)   *P* Value[a](#jah34777-note-0008){ref-type="fn"}
  --------------------------------------------- -------------------------------- ---------------------------------- --------------------------------------------------
  Men                                           4 (100)                          10 (40)                            0.042
  White                                         4 (100)                          24 (96)                            0.862
  Age at CPET, y                                42.1 (14.4)                      38.2 (23.8)                        0.343
  Proband                                       3 (75)                           23 (92)                            0.371
  Pathogenic mutation, any                      1 (25)                           17 (68)                            0.139
  Age at presentation, y                        41.0 (22.0)                      25.8 (21.2)                        0.312
  Age at meeting task force criteria, y         41.0 (22.0)                      30.8 (20.1)                        0.487
  No. of major criteria met                     3.5 (2.0)                        3.0 (2.0)                          0.897
  No. of minor criteria met                     3.0 (1.5)                        3.0 (3.0)                          0.846
  Total No. of criteria met                     6.0 (3.5)                        6.0 (3.0)                          0.749
  Type of presentation                                                                                              1.000
  Sudden cardiac arrest                         0 (0)                            1 (4)                              
  Symptomatic                                   4 (100)                          19 (76)                            
  Asymptomatic                                  0 (0)                            5 (20)                             
  β Blocker                                     2 (50)                           22 (88)                            0.127
  ACEi/ARB                                      3 (75)                           11 (44)                            0.330
  Aldosterone receptor blocker                  0 (0)                            6 (24)                             0.553
  Antiarrhythmic                                1 (25)                           13 (52)                            0.598
  ICD                                           3 (75)                           20 (80)                            1.000
  Clinical heart failure                        4 (100)                          13 (52)                            0.121
  LVEF, %                                       47.5 (22.5)                      55.0 (5.0)                         0.255
  LVEF \<45%                                    2 (50)                           4 (16)                             0.180
  Left ventricular end diastolic diameter, cm   4.9 (0.1)                        4.94 (0.7)                         0.824
  Moderate/severe RV dysfunction                3 (75)                           11 (44)                            0.330
  Moderate/severe RV dilation                   4 (100)                          11 (44)                            0.100
  Absolute pVO~2~, mL/min                       877 (301)                        1911 (594)                         
  Normalized pVO~2~, mL/kg per min              11.7 (0.7)                       22.8 (8.4)                         
  Predicted VO~2~ (n=27), %                     30.5 (17)                        83.2 (38)                          
  Ve/VCO~2~ slope (n=26)                        51.0 (26.4)                      29.6 (6.1)                         0.009
  VO~2~ at AT (n=26), mL/kg per min             8.4 (1.6)                        15.0 (6.2)                         0.006
  Respiratory exchange ratio                    1.17 (0.16)                      1.16 (0.10)                        0.727
  Peak heart rate, beats per min                130 (24)                         150 (37)                           0.311
  Predicted heart rate, %                       75.5 (18.6)                      82 (19)                            0.569

Categorical variables are expressed as number (percentage). Continuous variables are expressed as median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AT, anabolic threshold; CPET, cardiopulmonary exercise testing; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; pVO~2~, peak VO~2~; RV, right ventricle; Ve/VCO~2~ slope, ventilatory efficiency; VO~2~, oxygen consumption.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

###### 

Comparison of Patient Characteristics Based on Percentage Predicted pVO~2~

  Characteristic                              pVO~2~ \>70% (n=18)   pVO~2~ ≤70% (n=11)   *P* Value[a](#jah34777-note-0011){ref-type="fn"}
  ------------------------------------------- --------------------- -------------------- --------------------------------------------------
  Men                                         6 (33)                8 (73)               0.042
  White                                       17 (94)               11 (100)             0.621
  Age at CPET, y                              39.6 (28.7)           38.3 (14.6)          0.857
  Proband                                     18 (100)              8 (73)               0.371
  Pathogenic mutation, any                    11 (61)               7 (64)               0.139
  Age at presentation, y                      29.1 (22.5)           25.8 (24.0)          0.857
  Age at meeting task force criteria, y       35.2 (22.7)           30.8 (22.0)          0.686
  No. of major criteria met                   3.0 (2.0)             3.0 (2.0)            0.729
  No. of minor criteria met                   3.0 (3.0)             4.0 (3.0)            0.872
  Total No. of criteria met                   6.0 (2.0)             7.0 (3.0)            0.480
  Type of presentation                                                                   0.598
  Sudden cardiac arrest                       1 (6)                 0 (0)                
  Symptomatic                                 15 (83)               8 (73)               
  Asymptomatic                                2 (11)                3 (27)               
  β Blocker                                   15 (83)               9 (82)               0.127
  ACEi/ARB                                    8 (44)                6 (55)               0.330
  Aldosterone receptor blocker                3 (17)                3 (27)               0.553
  Antiarrhythmic                              9 (50)                5 (45)               0.598
  ICD                                         13 (72)               10 (91)              1.000
  Clinical heart failure                      8 (44)                9 (82)               0.121
  LVEF, %                                     58 (5)                55 (23)              0.071
  LVEF \<45%                                  2 (11)                4 (36)               0.180
  Left ventricle end diastolic diameter, cm   4.8 (0.8)             5.1 (1.0)            0.016
  Moderate/severe RV dysfunction              7 (39)                7 (64)               0.330
  Moderate/severe RV dilation                 8 (44)                7 (64)               0.100
  Absolute pVO~2~, mL/min                     1843 (892)            1554 (676)           0.150
  Normalized pVO~2~, mL/kg per min            25.6 (14.6)           19.0 (9.2)           0.002
  Ve/VCO~2~ slope                             30.0 (4.2)            29.6 (13.5)          0.916
  VO~2~ at AT (n=26), mL/kg per min           15.9 (7.1)            11.8 (5.6)           0.016
  Respiratory exchange ratio                  1.16 (0.09)           1.15 (0.20)          0.822
  Peak heart rate, beats per min              160 (25)              127 (23)             0.025
  Predicted heart rate, %                     85 (10)               70 (18)              0.021

Categorical variables are expressed as number (percentage). Continuous variables are expressed as median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AT, anabolic threshold; CPET, cardiopulmonary exercise testing; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; pVO~2~, peak VO~2~; RV, right ventricle; Ve/VCO~2~ slope, ventilatory efficiency; VO~2~, oxygen consumption.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

When compared by Ve/VCO~2~ slope, patients with Ve/VCO~2~ slope ≤34 (n=26) had no observed differences from patients with Ve/VCO~2~ slope \>34 (n=9) in regard to age, sex, race, or mutation presence (Table [5](#jah34777-tbl-0005){ref-type="table"}). There was a trend toward patients with Ve/VCO~2~ slope \>34 more frequently having clinical HF (8/9 \[89%\] versus 13/26 \[50%\]; *P*=0.056) and more moderate/severe RV dilation (7/9 \[78%\] versus 10/26 \[38%\]; *P*=0.060). Those with Ve/VCO~2~ slope \>34 also had a lower pVO~2~ than those with Ve/VCO~2~ ≤34 (15.9 \[IQR, 10.6\] versus 21.8 \[IQR, 12.0\] mL/kg per minute; *P*=0.025). Sensitivity analysis using higher Ve/VCO~2~ cutoff (≤36 versus \>36) is described in Table [6](#jah34777-tbl-0006){ref-type="table"} and showed similar results as well as a statistically significant higher degree of RV dilation in the Ve/VCO~2~ slope \>36 group. Invasive hemodynamic data were available in 17 patients. A statistically significant inverse correlation between cardiac output and Ve/VCO~2~ slope was noted, with *r* ^2^=0.5 and *P*=0.002.

###### 

Comparison of Patient Characteristics Based on Ve/VCO~2~ Slope Category

  Characteristic                              Ve/VCO~2~ Slope ≤34 (n=26)   Ve/VCO~2~ Slope \>34 (n=9)   *P* Value[a](#jah34777-note-0014){ref-type="fn"}
  ------------------------------------------- ---------------------------- ---------------------------- --------------------------------------------------
  Men                                         13 (50)                      6 (67)                       0.460
  White                                       25 (96)                      9 (100)                      0.740
  Age at CPET, y                              38.8 (24.3)                  42.9 (14.0)                  0.706
  Proband                                     23 (88)                      8 (89)                       1.000
  Pathogenic mutation, any                    19 (73)                      6 (67)                       0.694
  Age at presentation, y                      26.1 (21.1)                  26.2 (18.8)                  0.678
  Age at meeting task force criteria, y       33.3 (23.4)                  26.2 (20.4)                  0.850
  No. of major criteria met                   3.0 (2.0)                    3.0 (1.0)                    0.110
  No. of minor criteria met                   3.0 (3.0)                    3.0 (1.0)                    0.427
  Total No. of criteria met                   6.0 (3.0)                    6.0 (4.0)                    0.717
  Type of presentation                                                                                  0.410
  Sudden cardiac arrest                       2 (8)                        1 (11)                       
  Symptomatic                                 18 (69)                      8 (89)                       
  Asymptomatic                                6 (23)                       0 (0)                        
  β Blocker                                   23 (88)                      7 (78)                       0.586
  ACEi/ARB                                    16 (62)                      4 (44)                       0.451
  Aldosterone receptor blocker                6 (23)                       2 922)                       1.000
  Antiarrhythmic                              12 (46)                      6 (67)                       0.443
  ICD                                         22 (85)                      9 (100)                      0.553
  Clinical heart failure                      13 (50)                      8 (89)                       0.056
  LVEF, %                                     55 (15)                      55 (10)                      0.847
  LVEF \<45%                                  6 (23)                       2 (22)                       1.000
  Left ventricle end diastolic diameter, cm   5.1 (0.8)                    4.8 (0.6)                    0.059
  Moderate/severe RV dysfunction              13 (50)                      4 (44)                       1.000
  Moderate/severe RV dilation                 10 (38)                      7 (78)                       0.060
  Absolute pVO~2~, mL/min                     1743 (740)                   1255 (344)                   0.006
  Normalized pVO~2~, mL/kg per min            21.8 (12.0)                  15.9 (10.6)                  0.025
  Predicted peak VO~2~, %                     73 (35)                      60 (36)                      0.071
  VO~2~ at AT (n=32), mL/kg per min           13.5 (5.4)                   10.2 (6.1)                   0.041
  Respiratory exchange ratio                  1.10 (0.16)                  1.11 (0.11)                  0.692
  Peak heart rate, beats per min              152 (52)                     121 (20)                     0.395
  Predicted heart rate, %                     82 (25)                      68 (17)                      0.282

Categorical variables are expressed as number (percentage). Continuous variables are expressed as median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AT, anabolic threshold; CPET, cardiopulmonary exercise testing; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; pVO~2~, peak VO~2~; RV, right ventricle; Ve/VCO~2~ slope, ventilatory efficiency; VO~2~, oxygen consumption.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

###### 

Comparison of Patient Characteristics Based on Ve/VCO~2~ Slope Category Using 36 as the Cutoff

  Characteristic                              Ve/VCO~2~ Slope ≤36 (n=29)   Ve/VCO~2~ Slope \>36 (n=6)   *P* Value[a](#jah34777-note-0017){ref-type="fn"}
  ------------------------------------------- ---------------------------- ---------------------------- --------------------------------------------------
  Men                                         14 (48)                      5 (83)                       0.460
  White                                       28 (97)                      6 (100)                      1.000
  Age at CPET, y                              38.6 (21.0)                  43.1 (25.5)                  0.358
  Proband                                     26 (90)                      5 (83)                       1.000
  Pathogenic mutation, any                    21 (72)                      4 (67)                       0.694
  Age at presentation, y                      23.9 (21.2)                  33.4 (20.4)                  0.484
  Age at meeting task force criteria, y       31.5 (22.7)                  33.4 (20.4)                  0.965
  No. of major criteria met                   3.0 (2.0)                    4.0 (2.0)                    0.039
  No. of minor criteria met                   3.0 (3.0)                    3.0 (3.0)                    0.964
  Total No. of criteria met                   6.0 (3.0)                    8.0 (4.0)                    0.215
  Type of presentation                                                                                  0.586
  Sudden cardiac arrest                       3 (10)                       0 (0)                        
  Symptomatic                                 20 (69)                      6 (100)                      
  Asymptomatic                                6 (21)                       0 (0)                        
  β Blocker                                   25 (86)                      5 (83)                       0.586
  ACEi/ARB                                    17 (59)                      3 (50)                       0.451
  Aldosterone receptor blocker                7 (24)                       1 (17)                       1.000
  Antiarrhythmic                              14 (48)                      4 (67)                       0.443
  ICD                                         25 (86)                      6 (100)                      0.553
  Clinical heart failure                      16 (55)                      5 (83)                       0.056
  LVEF, %                                     55 (15)                      55 (10)                      0.755
  LVEF \<45%                                  7 (24)                       1 (17)                       1.000
  Left ventricle end diastolic diameter, cm   5.0 (0.6)                    4.7 (0.7)                    0.048
  Moderate/severe RV dysfunction              13 (45)                      4 (67)                       1.000
  Moderate/severe RV dilation                 11 (38)                      6 (100)                      0.060
  Absolute pVO~2~, mL/min                     1682 (695)                   1236 (344)                   0.049
  Normalized pVO~2~, mL/kg per min            22.5 (9.3)                   14.0 (5.1)                   0.022
  Predicted VO~2~, %                          73 (32)                      49 (41)                      0.025
  VO~2~ at AT (n=32), mL/kg per min           13.7 (4.7)                   9.43 (2.6)                   0.032
  Respiratory exchange ratio                  1.10 (0.16)                  1.10 (0.07)                  0.948
  Peak heart rate, beats per min              144 (52)                     121 (19)                     0.220
  Predicted heart rate, %                     82 (24)                      68 (17)                      0.237

Categorical variables are expressed as number (percentage). Continuous variables are expressed as median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AT, anabolic threshold; CPET, cardiopulmonary exercise testing; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; pVO~2~, peak VO~2~; RV, right ventricle; Ve/VCO~2~ slope, ventilatory efficiency; VO~2~, oxygen consumption.

Continuous variables were analyzed using Wilcoxon rank‐sum test (Mann‐Whitney U test), and categorical data were analyzed using Fisher exact test.

Long‐Term Outcomes {#jah34777-sec-0018}
------------------

Median follow‐up time from the last CPET was 252 (IQR, 555) days. Ten patients (26%) met the end point of heart transplantation; there were 2 deaths, both occurring after heart transplantation. No significant differences in baseline demographics (Table [1](#jah34777-tbl-0001){ref-type="table"}) or ability to exercise during CPET (as assessed by heart rate, exercise duration, and RER) (Table [2](#jah34777-tbl-0002){ref-type="table"}) were seen between those who did and did not undergo heart transplantation. All 5 patients with pathogenic mutation who also underwent heart transplantation had a *PKP2* gene mutation; this, however, was not significantly different than the proportion of patients with a *PKP2* mutation who did not receive a transplant. Patients who underwent heart transplantation were more likely to have had clinical HF (10/10 \[100%\] versus 13/28 \[46%\]; *P*=0.003). Eight patients were transplanted for advanced HF (New York Heart Association functional class IV symptoms), one for incessant VT leading to HF, and one for a combination of VT and significant symptomatic RV failure. Of the 10 patients who underwent transplant, 7 were transplanted within 1 year of their last CPET, 2 within 18 months, and 1 not until 4 years later. There was no difference between groups in number of submaximal tests (3/10 \[30%\] versus 6/28 \[21%\]; *P*=0.673).

Kaplan‐Meier curves for transplant‐free survival based on pVO~2~ and Ve/VCO~2~ slope are shown in Figure [1](#jah34777-fig-0001){ref-type="fig"}. Patients with pVO~2~ ≤14 mL/kg per minute had similar transplant‐free survival as patients with pVO~2~ \>14 mL/kg per minute (n=29; hazard ratio, 3.38 \[95% CI, 0.75--15.19\]; log‐rank *P*=0.092; Figure [1](#jah34777-fig-0001){ref-type="fig"}A). Patients with Ve/VCO~2~ slope \>34 had worse transplant‐free survival compared with patients with Ve/VCO~2~ slope ≤34 (n=35; hazard ratio, 6.57 \[95% CI, 1.28--33.72\]; log‐rank *P*=0.010; Figure [1](#jah34777-fig-0001){ref-type="fig"}B). There was no difference based on percentage predicted pVO~2~ ≤70% versus \>70% (n=29; hazard ratio, 3.27 \[95% CI, 0.60--18.00\]; log‐rank *P*=0.148; Figure [2](#jah34777-fig-0002){ref-type="fig"}A). Transplant‐free survival remained significantly different with sensitivity analysis using Ve/VCO~2~ slope cutoff \>36 (n=35; hazard ratio, 4.25 \[95% CI, 1.06--17.09\]; log‐rank *P*=0.026; Figure [2](#jah34777-fig-0002){ref-type="fig"}B).

![Transplant‐free survival based on peak oxygen consumption (VO ~2~) (**A**) and ventilatory efficiency (Ve/VCO ~2~ slope) (**B**). Comparison of survival curves for patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia undergoing cardiopulmonary exercise testing based on peak VO ~2~ (≤14 vs \>14 mL/kg per minute) and Ve/VCO ~2~ slope (≤34 vs \>34). HR indicates hazard ratio.](JAH3-9-e013695-g001){#jah34777-fig-0001}

![Transplant‐free survival based on percentage predicted peak oxygen consumption (pVO ~2~) (**A**) and ventilatory efficiency (Ve/VCO ~2~ slope) (**B**). Comparison of survival curves for patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia undergoing cardiopulmonary exercise testing based on percentage predicted pVO ~2~ (\<70% vs ≥70%) and Ve/VCO ~2~ slope (≤36 vs \>36). HR indicates hazard ratio.](JAH3-9-e013695-g002){#jah34777-fig-0002}

Discussion {#jah34777-sec-0019}
==========

This study is the first, to our knowledge, to examine CPET in patients with ARVC/D. We describe CPET safety, performance characteristics, and outcomes in this special patient population. We found that CPET is safe to perform even in patients with high arrhythmic burden and history of life‐threatening ventricular arrhythmias. We also demonstrated that Ve/VCO~2~ slope, rather than pVO~2~, is associated with clinical HF and transplant‐free survival. This study provides important prognostic insight for patients with ARVC/D who are increasingly presenting with progressive HF as arrhythmic mortality decreases.

Safety of Exercise Testing in ARVC/D {#jah34777-sec-0020}
------------------------------------

CPET was safe without any sustained arrhythmias in this ARVC/D cohort. Exercise testing is generally considered a safe procedure in appropriately selected patients, with surveys suggesting 0 to 6 deaths or cardiac arrests and 2 to 10 myocardial infarctions per 10 000 tests.[7](#jah34777-bib-0007){ref-type="ref"} The ARVC/D population generally lacks coronary artery risk factors, as confirmed in our current cohort, so myocardial infarction is less likely when compared with the broader population referred for exercise testing.

ARVC/D is a disease of the cardiac desmosome, which are specialized adhesion junctions providing the mechanical connection between cardiac myocytes. In this study, two thirds of patients carried a desmosomal mutation and just over half of those were in the *PKP2* gene. Alterations in desmosomal structure as well as increased RV wall stress during exercise have been implicated as triggers for arrhythmia in ARVC/D.[1](#jah34777-bib-0001){ref-type="ref"}, [14](#jah34777-bib-0014){ref-type="ref"} It is well established that non‐ARVC/D patients with severe LV systolic dysfunction also have an increased risk of ventricular arrhythmia.[15](#jah34777-bib-0015){ref-type="ref"}, [16](#jah34777-bib-0016){ref-type="ref"} Despite this inherent risk, in the HF‐ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training Study), only 2 of 4411 (0.04%) CPETs performed in patients with LV ejection fraction \<35% were complicated by ventricular arrhythmia, and only 27 (0.6%) were stopped for nonsustained VT.[17](#jah34777-bib-0017){ref-type="ref"} However, compared with our ARVC/D cohort, in which two thirds had a prior life‐threatening arrhythmia, in HF‐ACTION only 23% of those with an ICD had a history of ICD firing before CPET.[17](#jah34777-bib-0017){ref-type="ref"} Despite this, there were no sustained ventricular arrhythmias observed during or immediately after CPET in our cohort. Premature ventricular contractions (PVCs) may be seen more commonly, for example, at a rate of 55% in a large study of non‐HF patients referred for exercise testing primarily for ischemia.[18](#jah34777-bib-0018){ref-type="ref"} In our study, 14% had PVCs noted during testing. Overall, the rate of arrhythmic events in our cohort was similar to or lower than in previous studies in other populations.

Exercise alone can worsen arrhythmic outcomes in ARVC/D, and work from our group has demonstrated the relationship between longitudinal exercise exposure and disease progression, which has resulted in guidelines for exercise limitation in ARVC/D.[14](#jah34777-bib-0014){ref-type="ref"} These guidelines can create hesitation for both clinician referral and patient participation (perhaps contributing to several submaximal tests in our cohort) for CPET risk stratification. Therefore, this is an appropriate setting to rely more so on submaximal parameters, such as Ve/VCO~2~ slope. Also, the ill effects of exercise on ARVC/D are related to longer‐term exercise exposure (in units of hours per year) and aerobic intensity, whereas the exercise required for CPET is of short duration (average exercise time of 10.5 minutes in present study). Of note, in our study, 76% (29 patients) were able to perform a maximal test (RER ≥1.05).

Ve/VCO~2~ Slope and RV Cardiomyopathy {#jah34777-sec-0021}
-------------------------------------

Early work on CPET in HF mostly focused on pVO~2~ in LV systolic dysfunction, although correlation of pVO~2~ with survival has also been seen in disease models with pure RV systolic dysfunction.[19](#jah34777-bib-0019){ref-type="ref"} However, interpretation of pVO~2~ is limited by need for maximal exercise effort, which was not achieved in 24% of our ARVC/D cohort. In ARVC/D in particular, as discussed above, achievement of an adequate RER can be limited for several reasons, including patient counseling to avoid maximal exercise, concern for arrhythmia or ICD intervention at higher heart rates, and heavy β blockade (84% of patients on β blocker in this study) and antiarrhythmic use. Although percentage predicted pVO~2~ may be a better measure in a younger patient population (such as ARVC/D) than absolute normalized pVO~2~, our sensitivity analysis using percentage predicted pVO~2~ did not demonstrate predictive ability and this measurement also relies on maximum exercise. Therefore, a submaximal CPET parameter may be more suited to use in the ARVC/D population (namely, Ve/VCO~2~ slope).

Although there is an established relationship between RV function and Ve/VCO~2~ slope, to date, most analyses have been limited to patients with concomitant left‐sided HF and/or those with pulmonary hypertension and RV pressure overload.[13](#jah34777-bib-0013){ref-type="ref"}, [20](#jah34777-bib-0020){ref-type="ref"}, [21](#jah34777-bib-0021){ref-type="ref"} In one such study, Lewis et al studied 30 patients with left‐sided heart disease with simultaneous CPET and invasive hemodynamic monitoring and showed an inverse correlation between Ve/VCO~2~ slope and RV ejection fraction, as measured using radionuclide ventriculography.[13](#jah34777-bib-0013){ref-type="ref"} It is less clear, however, if Ve/VCO~2~ slope increases as a result of pulmonary vascular disease, RV dysfunction, or both. Our study presented the unique opportunity to study this relationship in a patient population enriched with intrinsic RV pathological features, not caused by RV pressure overload from left‐sided heart disease or pulmonary vascular disease. Interestingly, we found an inverse relationship between pulmonary artery systolic pressure and Ve/VCO~2~ slope (*r* ^2^=0.27; *P*=0.031). However, the clinical significance of this finding may be limited, as none of our patients had truly elevated pulmonary artery pressure (pulmonary artery systolic pressure range, 11--32 mm Hg; mean pulmonary artery pressure, all \<20 mm Hg) and we only had a subset of patients with invasive hemodynamic data.

Although our data did not demonstrate a clear relationship between RV function and Ve/VCO~2~ slope, we were limited by relying on clinical echocardiography and resting state measurements of RV function. Indeed, there is increasing evidence that RV reserve may be a more robust way to assess RV function, correlating better with both symptoms and outcomes.[22](#jah34777-bib-0022){ref-type="ref"}, [23](#jah34777-bib-0023){ref-type="ref"}, [24](#jah34777-bib-0024){ref-type="ref"}, [25](#jah34777-bib-0025){ref-type="ref"}, [26](#jah34777-bib-0026){ref-type="ref"} Using multibeat pressure‐volume relations, the gold standard to assess ventricular function, Hsu and colleagues found an inverse relationship between Ve/VCO~2~ slope and both RV--pulmonary artery coupling and RV reserve.[21](#jah34777-bib-0021){ref-type="ref"} Guazzi et al studied 97 patients with HF and grouped them first on the basis of whether they had normal RV function using tricuspid annular plane systolic excursion and then on the basis of whether those with abnormal tricuspid annular plane systolic excursion improved with exercise.[20](#jah34777-bib-0020){ref-type="ref"} They demonstrated not only increasing Ve/VCO~2~ slope with impaired RV reserve but also a higher percentage of symptomatic HF (based on New York Heart Association class) in the reduced RV reserve group. One population that can demonstrate similar physiological features to ARVC/D is adult congenital heart disease with RV involvement, with or without pulmonary vascular changes. DeFaria Yeh et al studied a heterogeneic group of 147 patients with adult congenital heart disease and found that RV reserve, measured using exercise CPET and radionuclide ventriculography, was a powerful predictor of event‐free survival.[27](#jah34777-bib-0027){ref-type="ref"}

These studies, combined with our present data, suggest that impaired RV reserve may be contributing to HF symptoms in ARVC/D. Pathologically, contractile cardiomyocytes are replaced by noncontractile fibrous and fatty tissue in ARVC/D, thus decreasing the ability of the heart to accommodate increased demands of exercise, with possible resultant symptoms. As we demonstrated, worse Ve/VCO~2~ slope tended to correlate with clinical HF, emphasizing the importance of recognizing symptomatic HF in patients with ARVC/D because this may be a marker for future need for advanced therapies.[4](#jah34777-bib-0004){ref-type="ref"} In addition, longer‐term management can be aided by Ve/VCO~2~ slope by supplementing the subjective symptoms with objective parameters of cardiac function.

Limitations {#jah34777-sec-0022}
-----------

The main limitations of this study stem from its observational and retrospective design, reliance on registry data, and small sample size. Given the referral nature of our ARVC/D program and the rarity of the disease, we elected to include CPETs done at other institutions. This limits our ability to propose any conclusions based on exercise time or protocol, which can impact pVO~2~ measurements.[28](#jah34777-bib-0028){ref-type="ref"} After exclusion of submaximal tests for outcome analyses, we were left with a small number in the group with pVO~2~ ≤14 mL/kg per minute, likely limiting our ability to detect significant differences between groups if they exist. Last, our assessment of RV function was based on echocardiogram at rest rather than during exercise. Given the potential role of impaired RV reserve in ARVC/D, future studies should incorporate dynamic assessment of RV function during CPET under a standardized protocol for exercise and RV assessment. Despite these limitations, this is the first study to report safety, clinical characteristics, and outcomes of patients with ARVC/D undergoing CPET.

Conclusions {#jah34777-sec-0023}
===========

CPET is safe to perform in patients with arrhythmogenic RV cardiomyopathy/dysplasia. In addition, Ve/VCO~2~ slope is associated with transplant‐free survival and allows submaximal testing in a patient cohort who may hesitate to perform maximal exercise. With increasing incidence of HF in ARVC/D, this study encourages providers to incorporate CPET into risk stratification of these patients. Future prospective multicenter studies are needed to further elucidate the prognostic value of serial CPET in ARVC/D.
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